Hills Bank & Trust Co Takes $13.72 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Hills Bank & Trust Co acquired a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor acquired 1,027,830 shares of the company's stock, valued at approximately $13,722,000. Perspective Therapeutics comprises approximately 1.0% of Hills Bank & Trust Co's investment portfolio, making the stock its 21st biggest position. Hills Bank & Trust Co owned approximately 1.65% of Perspective Therapeutics as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. US Bancorp DE raised its position in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company's stock worth $88,000 after purchasing an additional 3,866 shares during the period. Taylor & Morgan Wealth Management LLC purchased a new position in shares of Perspective Therapeutics in the third quarter worth about $400,000. Trueblood Wealth Management LLC bought a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at about $217,000. Nicholson Wealth Management Group LLC purchased a new stake in Perspective Therapeutics during the 3rd quarter valued at about $21,390,000. Finally, nVerses Capital LLC bought a new position in Perspective Therapeutics during the 3rd quarter worth approximately $57,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Stock Up 2.4 %

Shares of CATX traded up $0.28 on Friday, reaching $12.09. The stock had a trading volume of 482,084 shares, compared to its average volume of 683,026. The company's 50-day moving average price is $13.45. Perspective Therapeutics, Inc. has a 12-month low of $2.20 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04. The business had revenue of $0.53 million for the quarter. Equities analysts anticipate that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on CATX. Bank of America initiated coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They issued a "buy" rating and a $24.00 price objective for the company. Wedbush reissued an "outperform" rating and set a $20.00 price target on shares of Perspective Therapeutics in a research report on Thursday, October 24th. UBS Group assumed coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They issued a "buy" rating and a $20.00 price objective on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Finally, Royal Bank of Canada cut their target price on Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating on the stock in a research note on Friday, August 16th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $20.63.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.